Department of Cardiovascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China.
Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4623-4631.
To investigate the expression of matrix metalloproteinase-7 (MMP-7) in abdominal aortic aneurysm (AAA) with hypertension, and the clinical efficacy of endovascular exclusion.
Seventy-two cases of AAA with hypertension were retrospectively analyzed. Patients were divided into the observation group (34 cases) and control group (38 cases). The control group was treated by AAA incision with artificial vascular replacement, while the observation group was treated by endovascular graft exclusion. Over the same period, 72 age- and sex-matched healthy adults and 72 patients with hypertension were selected. MMP-7 expression in patients with hypertension, aneurysm associated with hypertension, and healthy controls were measured by ELISA and immunohistochemical staining.
ELISA showed that serum MMP-7 levels of patients with an aneurysm were significantly higher than those of patients with simple hypertension and healthy controls (p<0.05). The operative time, blood loss, and blood transfusion in the observation group were significantly lower than those in the control group (p<0.05). At the 1-month follow-up, the prevalence of pulmonary infection, incision infection, lower limb thrombosis, and lower limb weakness in the observation group were significantly lower than in the control group (p<0.05). The quality of life scores in the observation group after 1 and 3 months was significantly higher than those in the control group (p<0.05). Immunohistochemistry showed that the expression of MMP-7 in aneurysm tissue was significantly higher than in normal tissue. The expression of MMP-7 in the two groups was significantly decreased compared with before surgery (p<0.05).
The detection of MMP-7 expression in hypertensive patients is an early marker of the occurrence of AAA. The use of endovascular exclusion for the treatment of AAA with hypertension is minimally invasive and safe. Furthermore, postoperative vital signs of patients are stable, and the quality of life is improved.
研究基质金属蛋白酶-7（MMP-7）在高血压性腹主动脉瘤（AAA）中的表达及血管内隔绝术的临床疗效。
回顾性分析 72 例高血压性 AAA 患者，将患者分为观察组（34 例）和对照组（38 例）。对照组采用 AAA 切开人工血管置换治疗，观察组采用血管内移植物隔绝术治疗。同期选取 72 例年龄、性别匹配的健康成年人和 72 例高血压患者。采用 ELISA 和免疫组化染色法检测高血压患者、高血压合并动脉瘤患者和健康对照组 MMP-7 的表达。
ELISA 结果显示，动脉瘤患者血清 MMP-7 水平明显高于单纯高血压患者和健康对照组（p<0.05）。观察组手术时间、术中出血量、输血量均明显低于对照组（p<0.05）。观察组术后 1 个月肺部感染、切口感染、下肢血栓、下肢无力的发生率明显低于对照组（p<0.05）。观察组术后 1、3 个月的生活质量评分明显高于对照组（p<0.05）。免疫组化结果显示，动脉瘤组织中 MMP-7 的表达明显高于正常组织，两组 MMP-7 的表达均明显低于术前（p<0.05）。
检测 MMP-7 在高血压患者中的表达是 AAA 发生的早期标志物。血管内隔绝术治疗高血压性 AAA 微创、安全，术后患者生命体征稳定，生活质量提高。
